Genitourinary Cancers | Specialty

The OncLive Genitourinary Cancer condition center page is a comprehensive resource for clinical news and expert insights across genitourinary (GU) malignancies, including renal cell carcinoma, urothelial carcinoma, and prostate cancer. This section features news articles, interviews in written and video format, and podcasts that focus on the evolving treatment paradigm of GU cancers and emerging research.

Sequencing Therapy With ADT Combinations

March 13th 2018

Newly Diagnosed Metastatic Prostate Cancer Treatment

March 13th 2018

Risk Stratification in Nonmetastatic Prostate Cancer

March 13th 2018

Challenges Associated With ADT for Prostate Cancer

March 13th 2018

Considerations for Initiating ADT in Prostate Cancer

March 13th 2018

Dr. Bellmunt on PD-L1 Data in Bladder Cancer

March 13th 2018

Joaquim Bellmunt, MD, PhD, associate professor of medicine, Harvard Medical School, director, Bladder Cancer Center, Dana-Farber Cancer Institute, discusses PD-L1 data with pembrolizumab (Keytruda) in patients with bladder cancer.

Dr. Gupta on the Role of Surgery in Bladder Cancer

March 12th 2018

Amit Gupta, MD, urologic oncologist, Department of Surgery, Cedars-Sinai Medical Center, discusses how the use of immunotherapy agents is altering the role of surgery in bladder cancer and the need for Bacillus Calmette-Guérin (BCG) alternatives.

Cytoreductive Nephrectomy Retains Role in Modern RCC Era

March 10th 2018

James Wysock, MD, discusses the evolution of cytoreductive nephrectomy in renal cell carcinoma.

Emerging Advances for Immunotherapy in Urothelial Cancer

March 9th 2018

Promise of DNA Vaccines in Bladder Cancer

March 9th 2018

Improving Responses to Immunotherapy in Bladder Cancer

March 9th 2018

Ongoing Immuno-Oncology Research in Bladder Cancer

March 9th 2018

A Therapeutic Revolution: Immunotherapy for Bladder Cancer

March 9th 2018

2018 Ushers in New Era of Prostate Cancer Treatment

March 9th 2018

Edwin M. Posadas, MD, discusses the evolution of prostate cancer therapy, including the earlier use of advanced-stage agents and the potential for immunotherapy in the field.

Renal Cell Carcinoma: An Evolving Treatment Landscape

March 8th 2018

Immunotherapeutic Combinations for mRCC: IMmotion-151

March 8th 2018

Personal Approaches to Treating Brain Metastasis in RCC

March 8th 2018

Metastatic RCC: Selecting Therapy at Recurrence

March 8th 2018

Metastatic Renal Cell Carcinoma: When to Switch Therapy

March 8th 2018

Defining Recurrence in Patients With Metastatic RCC

March 8th 2018